Levaquin is owned by Janssen Pharms.
Levaquin contains Levofloxacin.
Levaquin has a total of 2 drug patents out of which 2 drug patents have expired.
Expired drug patents of Levaquin are:
Levaquin was authorised for market use on 21 October, 2004.
Levaquin is available in solution;oral dosage forms.
The generics of Levaquin are possible to be released after 26 August, 2022.
|Patent Number||Company||Patent Title||Patent Expiry||Activity Alert|
|These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).|
|US6806256||JANSSEN PHARMS||Taste masked liquid pharmaceutical compositions|| |
(11 months ago)
|JANSSEN PHARMS||Taste masked liquid pharmaceutical compositions|| |
(5 months ago)
Market Authorisation Date: 21 October, 2004
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic